Accent Therapeutics Receives the US FDA’s IND Approval of ATX-559 for Treating Breast Cancer
Shots:
- Accent has received the IND clearance from the US FDA to begin the clinical evaluation of ATX-559 (DHX9 inhibitor). The company has also formed Clinical Advisory Board (CAB) for the guidance in its progress in the clinic
- The P-I/II trial will assess the safety tolerability, PK/PD & preliminary efficacy of ATX-559 for the treatment of patients with BRCA1- or BRCA2-deficient breast cancer and MSI-H and/or dMMR solid tumors (incl. colorectal, endometrial, gastric & other cancers); will begin in Q4’24
- Accent will also develop its another program under P-I study targeting KIF18A in chromosomally instable tumors, expected to begin in early 2025
Ref: Accent Therapeutics | Image: Accent Therapeutics
Related News:- Adcentrx Therapeutics Reports the US FDA’s IND Clearance of ADRX-0405 to Treat Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
